Posted by Michael Wonder on 24 Dec 2024
Datopotamab deruxtecan application in the EU for patients with advanced non-squamous non-small sell lung cancer voluntarily withdrawn
24 December 2024 - Daiichi Sankyo and AstraZeneca have voluntarily withdrawn the marketing authorisation application in the EU for datopotamab deruxtecan for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer based on the TROPION-Lung01 Phase 3 trial.
The decision to withdraw the marketing authorisation application was informed by feedback from the CHMP of the EMA.
